Work

Ustekinumab for the treatment of immune related cutaneous adverse events (ircAEs).

Year: 2023

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2023.41.16_suppl.e14702

Authors: Tara Maier, Stephanie Gu, Neil J. Shah, David M. Faleck, Mario E. Lacouture

Institution: Memorial Sloan Kettering Cancer Center

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4379283473

Cites:

Cited by: 1

Related to: 10